Cardiac Glycosides – The Review of Remedies in congestive heart Failure

2021 ◽  
pp. 187-190
Author(s):  
R. Ramasubramania Raja ◽  
Haribabu Y. ◽  
C.I Sajeeth
Keyword(s):  
Heart Failure ◽  
Blood Pressure ◽  
Coronary Artery Disease ◽  
Congestive Heart Failure ◽  
Coronary Artery ◽  
Heart Muscle ◽  
Cardiac Glycosides ◽  
Heart Diseases ◽  
Herbal Drugs ◽  
Artery Disease

Congestive heart failure, occurs when our heart muscle doesn't pump blood as well as it must. Certain conditions, such as narrowed arteries in your heart (coronary artery disease) or high blood pressure, gradually leave your heart too weak or stiff to fill and pump efficiently. Herbal drugs like digitalis, squill, and stropanthus commonly find the treatment of heart diseases. Caridio active glycosides like having the purpurea glycosides A and B present in the herb of digitalis, glucoscillaren A and scillarenase having the squill and strophanthus having strophanthoside.

scholarly journals Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

2003 ◽  
Vol 285 (4) ◽  
pp. H1576-H1581 ◽  
Author(s):  
Fraser D. Russell ◽  
Deborah Meyers ◽  
Andrew J. Galbraith ◽  
Nick Bett ◽  
Istvan Toth ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Artery Disease ◽  
Congestive Heart Failure ◽  
Coronary Artery ◽  
Pulmonary Artery ◽  
Femoral Artery ◽  
Aortic Root ◽  
Femoral Vein ◽  
Urotensin Ii ◽  
Artery Disease

Human urotensin-II (hU-II) is the most potent endogenous cardiostimulant identified to date. We therefore determined whether hU-II has a possible pathological role by investigating its levels in patients with congestive heart failure (CHF). Blood samples were obtained from the aortic root, femoral artery, femoral vein, and pulmonary artery from CHF patients undergoing cardiac catheterization and the aortic root from patients undergoing investigative angiography for chest pain who were not in heart failure. Immunoreactive hU-II (hU-II-ir) levels were determined with radioimmunoassay. hU-II-ir was elevated in the aortic root of CHF patients (230.9 ± 68.7 pg/ml, n = 21; P < 0.001) vs. patients with nonfailing hearts (22.7 ± 6.1 pg/ml, n = 18). This increase was attributed to cardiopulmonary production of hU-II-ir because levels were lower in the pulmonary artery (38.2 ± 6.1 pg/ml, n = 21; P < 0.001) than in the aortic root. hU-II-ir was elevated in the aortic root of CHF patients with nonischemic cardiomyopathy (142.1 ± 51.5 pg/ml, n = 10; P < 0.05) vs. patients with nonfailing hearts without coronary artery disease (27.3 ± 12.4 pg/ml, n = 7) and CHF patients with ischemic cardiomyopathy (311.6 ± 120.4 pg/ml, n = 11; P < 0.001) vs. patients with nonfailing hearts and coronary artery disease (19.8 ± 6.6 pg/ml, n = 11). hU-II-ir was significantly higher in the aortic root than in the pulmonary artery and femoral vein, with a nonsignificant trend for higher levels in the aortic root than in the femoral artery. The findings indicated that hU-II-ir is elevated in the aortic root of CHF patients and that hU-II-ir is cleared at least in part from the microcirculation.

Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease

1990 ◽  
Vol 66 (5) ◽  
pp. 608-613 ◽  
Author(s):  
Nader Dakak ◽  
Nabeel Makhoul ◽  
Moshe Y. Flugelman ◽  
Amnon Merdler ◽  
Habib Shehadeh ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Artery Disease ◽  
Congestive Heart Failure ◽  
Coronary Artery ◽  
Nitrate Tolerance ◽  
Artery Disease
Sign in / Sign up

Export Citation Format

Share Document